Emerging pathogenic role of group 3 innate lymphoid cells in inflammatory diseases.
- Author:
Hui-Xin XIE
1
;
Yun GUO
1
;
Hao-Jie ZHONG
1
;
Yi ZHOU
2
,
3
;
Xue-Qing YU
1
Author Information
1. The First Clinical Medical College, Guangdong Medical University, Zhanjiang 524023, China.
2. Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University
3. Key Laboratory of Nephrology, National Health Commission and Guangdong Province, Guangzhou 510080, China. zhouyi39@mail.sysu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Cytokines;
Immunity, Innate;
Interferon-gamma;
Intestines;
Lymphocytes
- From:
Acta Physiologica Sinica
2022;74(2):265-275
- CountryChina
- Language:Chinese
-
Abstract:
Group 3 innate lymphoid cells (ILC3) as a family member of innate lymphoid cells (ILCs), have been defined as novel innate immune cells in the past decade. ILC3 include a variety of heterogenous subsets with different phenotypes and functions, which are mainly distributed in barrier organs such as the intestine, lung and skin. They play an important role in immune regulation, tissue repair and lymphoid tissue formation. However, in various inflammatory diseases, ILC3 become dysregulated and participate in the pathogenesis through secreting a series of cytokines such as interleukin (IL)-17, IL-22, interferon-γ (IFN-γ) and granulocyte-macrophage colony-stimulating factor (GM-CSF) to modulate other immune cells and induce the formation of ectopic lymphoid structures. Therefore, it is of great significance to explore the phenotype and function of ILC3 in order to advance the understanding of inflammatory diseases and find new therapeutic targets. In this article, the phenotypic characteristics, biological functions and research progress of ILC3 in inflammatory diseases were reviewed.
